Navigation Links
Hill-Rom Reports Second Quarter Financial Results
Date:5/4/2009

(17.8) - (20.5) - - ----- ----- ----- ----- ----- Operating (loss) profit (462.5) 23.0 35.7 23.3 20.4 Other income/(expense), net (1.5) (2.0) (2.9) (1.3) (3.5) Income tax expense (1) 1.8 6.8 9.0 0.5 7.5 ------- ----- ----- ----- ---- (Loss) Income from continuing operations $(465.8) $14.2 $23.8 $21.5 $9.4 ------- ----- ----- ----- ---- Diluted (loss) earnings per share: (Loss) Earnings per share from continuing operations $(7.44) $0.23 $0.38 $0.34 $0.15 Average common shares outstanding - diluted (thousands) 62,578 62,808 62,734 62,655 62,566 Dividends per common share $0.1025 $0.1025 $0.1025 $0.1025 $0.2850 Consolidated Cash Flows from Operations (2) Cash flow from operations $55.1 $34.9 $43.3 $23.0 $84.1 Less: capital expenditures (16.0) (13.6) (25.3) (20.6) (30.7) ----- ----- ----- ----- ----- Consolidated free cash flow $39.1 $21.3 $18.0 $2.4 $53.4 ----- ----- ----- ---- ----- Cash and cash equivalents $84.6 $49.5 $221.7 $131.2 $145.9 Investments and investment securities (3) $44.8 $43.0 $45.6 $47.0 $49.4 Hill-Rom Capital Expenditures $16.0 $13.6 $25.3 $20.6 $28.7 Hill-Rom Depreciation & Amortization $24.8 $26.1 $28.1 $25.5 $25.5 (1) For fiscal year 2008, discrete tax benefits totaled $8.3 million ($0.13 per share), $7.8 million ($0.12 per share) of which was
'/>"/>
SOURCE Hill-Rom Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Hill-Rom to Present at the Bank of America 2009 Health Care Conference
2. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast
3. JCR and Hill-Rom Name First Nurse Scholar-in-Residence
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
6. Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year
7. DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 First Quarter Earnings Webcast
9. Hill-Rom Reports First Quarter Revenue of $350 Million and Announces Further Actions to Address Challenging Economic Environment
10. JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program
11. Hill-Rom Announces First Quarter 2009 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Children's Hospital Surgeon Receives Prestigious Paul Tessier Medal 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 3Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 4Health News:Authentidate Holding Corp. Completes Capital Raise 2Health News:Authentidate Holding Corp. Completes Capital Raise 3Health News:Happy Feet are Healthy Feet: Common Sense Tips on Taking Care of Your Feet to Survive the Holiday Season 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 1Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 2Meat Dairy Wont Up Odds for Breast Cancer 55638 1Meat Dairy Wont Up Odds for Breast Cancer 55638 2Meat Dairy Wont Up Odds for Breast Cancer 55638 3Pennsylvania Health Department Distributing Potassium Iodide to People Living Working Near Nuclear Power Plants 55636 1Pennsylvania Health Department Distributing Potassium Iodide to People Living Working Near Nuclear Power Plants 55636 2Pennsylvania Health Department Distributing Potassium Iodide to People Living Working Near Nuclear Power Plants 55636 3